New York, NY – According to filings with the U.S. Securities and Exchange Commission, Click Therapeutics is raising $52,123,200.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Klein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Click Therapeutics
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Clicks Digital Therapeutics enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Clicks industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click is also progressing a broad pipeline of prescription Digital Therapeutics across a variety of high-burden therapeutic areas, including Major Depressive Disorder, Schizophrenia, Acute Coronary Syndrome, Migraine, Chronic Pain, Insomnia, COPD, Obesity, and more.

To learn more about Click Therapeutics, visit http://clicktherapeutics.com/

Contact:
David Klein, Chief Executive Officer
646-248-7933
david@clicktherapeutics.com
https://www.linkedin.com/in/davidbklein/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved